Page 15 - Mylan EpiPen

Mylan’s Response to On-Going Criticism

In August 2016, in response to

mounting criticism, Mylan

increased financial assistance
available for some patients to

purchase EpiPens. However,
the up to $300 saving cards can

only be used by a small number of people who need the

drug, and no one on Medicaid. Mylan did nothing about the

high price which is still being paid by insurers, who

ultimately pass the cost onto consumers.

Mylan promised to introduce a generic version of EpiPen,

identical to the branded EpiPen but costing $300, half the

current price. But even at this it’s still 37 times what Wallace

and Krevitt estimated it costs to make.

"Our decision to launch a generic alternative to EpiPen is an

extraordinary commercial response," she said. "We

determined that bypassing the brand system in this case

and offering an additional alternative was the best option."

Source: http://Newsroom.Mylan.com